

Peter D Kwong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8885264/publications.pdf>

Version: 2024-02-01

318
papers

54,958
citations

2091

103
h-index

1764

218
g-index

361
all docs

361
docs citations

361
times ranked

29568
citing authors

#	ARTICLE	IF	CITATIONS
1	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. <i>Science Translational Medicine</i> , 2022, 14, eabj7125.	5.8	93
2	A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. <i>Emerging Microbes and Infections</i> , 2022, 11, 147-157.	3.0	25
3	A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination. <i>Nature Medicine</i> , 2022, 28, 373-382.	15.2	16
4	SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy. <i>MBio</i> , 2022, 13, e0322721.	1.8	48
5	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. <i>Cell</i> , 2022, 185, 1556-1571.e18.	13.5	179
6	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. <i>Science</i> , 2022, 376, eabn8897.	6.0	119
7	Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2. <i>Advanced Science</i> , 2022, , 2200063.	5.6	3
8	Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2. <i>Journal of Biological Chemistry</i> , 2022, 298, 101819.	1.6	9
9	GLYCO: a tool to quantify glycan shielding of glycosylated proteins. <i>Bioinformatics</i> , 2022, 38, 1152-1154.	1.8	2
10	Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-binding site. <i>Structure</i> , 2022, 30, 862-875.e4.	1.6	4
11	An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. <i>Science Translational Medicine</i> , 2022, 14, eabn6859.	5.8	31
12	Structure of an influenza group 2-neutralizing antibody targeting the hemagglutinin stem supersite. <i>Structure</i> , 2022, , .	1.6	1
13	<i>C</i> ₃ -Symmetric Aromatic Core of Griffithsin Is Essential for Potent Anti-HIV Activity. <i>ACS Chemical Biology</i> , 2022, 17, 1450-1459.	1.6	1
14	Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency. <i>Scientific Reports</i> , 2022, 12, 8433.	1.6	8
15	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. <i>PLoS ONE</i> , 2022, 17, e0268767.	1.1	18
16	Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. <i>EClinicalMedicine</i> , 2022, 48, 101477.	3.2	13
17	Highly protective antimalarial antibodies via precision library generation and yeast display screening. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	9
18	Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4. <i>PLoS Pathogens</i> , 2022, 18, e1010574.	2.1	6

#	ARTICLE	IF	CITATIONS
19	Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. <i>Structure</i> , 2022, 30, 1233-1244.e7.	1.6	13
20	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. <i>Science</i> , 2021, 371, .	6.0	49
21	Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. <i>Vaccines</i> , 2021, 9, 73.	2.1	24
22	Protective antibodies against human parainfluenza virus type 3 infection. <i>MAbs</i> , 2021, 13, 1912884.	2.6	13
23	A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. <i>MAbs</i> , 2021, 13, 1946918.	2.6	11
24	Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth. <i>Immunity</i> , 2021, 54, 324-339.e8.	6.6	36
25	Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. <i>IScience</i> , 2021, 24, 102047.	1.9	16
26	Single-Shot Vaccines against Bovine Respiratory Syncytial Virus (BRSV): Comparative Evaluation of Long-Term Protection after Immunization in the Presence of BRSV-Specific Maternal Antibodies. <i>Vaccines</i> , 2021, 9, 236.	2.1	8
27	Structural basis of malaria RFIN binding by LILRB1-containing antibodies. <i>Nature</i> , 2021, 592, 639-643.	13.7	8
28	Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	21
29	Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria. <i>Vaccines</i> , 2021, 9, 272.	2.1	16
30	Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. <i>Nature</i> , 2021, 593, 130-135.	13.7	1,904
31	Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base. <i>Cell Reports</i> , 2021, 35, 108937.	2.9	12
32	Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class. <i>Cell Reports</i> , 2021, 35, 108950.	2.9	54
33	Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. <i>Immunity</i> , 2021, 54, 769-780.e6.	6.6	37
34	High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19. <i>PLoS Pathogens</i> , 2021, 17, e1009431.	2.1	34
35	Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. <i>Cell Host and Microbe</i> , 2021, 29, 747-751.e4.	5.1	504
36	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. <i>Cell</i> , 2021, 184, 2955-2972.e25.	13.5	57

#	ARTICLE	IF	CITATIONS
37	Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. <i>Cell Host and Microbe</i> , 2021, 29, 819-833.e7.	5.1	444
38	Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses. <i>Frontiers in Immunology</i> , 2021, 12, 662909.	2.2	0
39	Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement. <i>Journal of Virology</i> , 2021, 95, .	1.5	3
40	Structures of HIV-1 Neutralizing Antibody 10E8 Delineate the Mechanistic Basis of Its Multi-Peak Behavior on Size-Exclusion Chromatography. <i>Antibodies</i> , 2021, 10, 23.	1.2	2
41	A non-affinity purification process for GMP production of prefusion-closed HIV-1 envelope trimers from clades A and C for clinical evaluation. <i>Vaccine</i> , 2021, 39, 3379-3387.	1.7	13
42	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. <i>Nature</i> , 2021, 595, 278-282.	13.7	154
43	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , 2021, 373, .	6.0	174
44	Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. <i>Structure</i> , 2021, 29, 655-663.e4.	1.6	52
45	Structural basis of LAIR1 targeting by polymorphic Plasmodium RIFINs. <i>Nature Communications</i> , 2021, 12, 4226.	5.8	1
46	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	56
47	N-terminal Transmembrane-Helix Epitope Tag for X-ray Crystallography and Electron Microscopy of Small Membrane Proteins. <i>Journal of Molecular Biology</i> , 2021, 433, 166909.	2.0	13
48	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. <i>Cell</i> , 2021, 184, 4203-4219.e32.	13.5	228
49	Blocking $\alpha 4 \beta 7$ integrin delays viral rebound in SHIV SF162P3-infected macaques treated with anti-HIV broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	11
50	Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS-CoV-2. <i>AICHE Journal</i> , 2021, 67, e17440.	1.8	4
51	Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	20
52	Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses. <i>Cell Reports</i> , 2021, 37, 109771.	2.9	38
53	SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. <i>Journal of Biological Chemistry</i> , 2021, 297, 101127.	1.6	9
54	Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain. <i>Cell Reports</i> , 2021, 37, 109928.	2.9	52

#	ARTICLE	IF	CITATIONS
55	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. <i>Nature Immunology</i> , 2021, 22, 1503-1514.	7.0	40
56	Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. <i>Cell Reports</i> , 2021, 37, 109922.	2.9	5
57	Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces. <i>Nature Communications</i> , 2021, 12, 6470.	5.8	3
58	Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies. <i>Immunity</i> , 2021, 54, 2859-2876.e7.	6.6	19
59	Structural Basis of Antibody Conformation and Stability Modulation by Framework Somatic Hypermutation. <i>Frontiers in Immunology</i> , 2021, 12, 811632.	2.2	3
60	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. <i>Cell Reports</i> , 2020, 33, 108322.	2.9	59
61	Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies. <i>IScience</i> , 2020, 23, 101711.	1.9	4
62	Removal of variable domain <i>N</i> -linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies. <i>MAbs</i> , 2020, 12, 1836719.	2.6	4
63	Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. <i>Cell Host and Microbe</i> , 2020, 28, 867-879.e5.	5.1	316
64	Antibody-guided structure-based vaccines. <i>Seminars in Immunology</i> , 2020, 50, 101428.	2.7	29
65	Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles. <i>Cell Host and Microbe</i> , 2020, 28, 880-891.e8.	5.1	153
66	Automated Design by Structure-Based Stabilization and Consensus Repair to Achieve Prefusion-Closed Envelope Trimers in a Wide Variety of HIV Strains. <i>Cell Reports</i> , 2020, 33, 108432.	2.9	32
67	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , 2020, 383, 1544-1555.	13.9	936
68	Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. <i>Nature</i> , 2020, 584, 450-456.	13.7	1,337
69	Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature. <i>Cell Reports</i> , 2020, 32, 107981.	2.9	15
70	A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. <i>Scientific Reports</i> , 2020, 10, 18149.	1.6	90
71	Identification and Structure of a Multidonor Class of Head-Directed Influenza-Neutralizing Antibodies Reveal the Mechanism for Its Recurrent Elicitation. <i>Cell Reports</i> , 2020, 32, 108088.	2.9	13
72	Distinct disease features in chimpanzees infected with a precore HBV mutant associated with acute liver failure in humans. <i>PLoS Pathogens</i> , 2020, 16, e1008793.	2.1	4

#	ARTICLE	IF	CITATIONS
73	Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide. <i>Vaccines</i> , 2020, 8, 765.	2.1	12
74	Disulfide stabilization of human norovirus GI.1 virus-like particles focuses immune response toward blockade epitopes. <i>Npj Vaccines</i> , 2020, 5, 110.	2.9	6
75	HIV-1 Envelope and MPER Antibody Structures in Lipid Assemblies. <i>Cell Reports</i> , 2020, 31, 107583.	2.9	60
76	The covalent SNAP tag for protein display quantification and low-pH protein engineering. <i>Journal of Biotechnology</i> , 2020, 320, 50-56.	1.9	4
77	Next-generation sequencing of the intrahepatic antibody repertoire delineates a unique B cell response in HBV-associated acute liver failure. <i>Journal of Viral Hepatitis</i> , 2020, 27, 847-851.	1.0	5
78	VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage. <i>Cell Host and Microbe</i> , 2020, 27, 531-543.e6.	5.1	23
79	Subnanometer structures of HIV-1 envelope trimers on aldrithiol-2-inactivated virus particles. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 726-734.	3.6	55
80	Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen. <i>Scientific Reports</i> , 2020, 10, 3032.	1.6	36
81	Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. <i>Cell Reports</i> , 2020, 31, 107488.	2.9	53
82	Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses. <i>Journal of Virology</i> , 2020, 94, .	1.5	21
83	A Single Shot Pre-fusion-Stabilized Bovine RSV F Vaccine is Safe and Effective in Newborn Calves with Maternally Derived Antibodies. <i>Vaccines</i> , 2020, 8, 231.	2.1	14
84	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. <i>SSRN Electronic Journal</i> , 2020, , 3639618.	0.4	3
85	A proof of concept for structure-based vaccine design targeting RSV in humans. <i>Science</i> , 2019, 365, 505-509.	6.0	207
86	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. <i>Cell</i> , 2019, 178, 567-584.e19.	13.5	106
87	Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates. <i>Scientific Reports</i> , 2019, 9, 14696.	1.6	30
88	cAb-Rep: A Database of Curated Antibody Repertoires for Exploring Antibody Diversity and Predicting Antibody Prevalence. <i>Frontiers in Immunology</i> , 2019, 10, 2365.	2.2	67
89	Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAbs lineage. <i>PLoS Pathogens</i> , 2019, 15, e1008005.	2.1	6
90	Blocking $\alpha 4 \beta 7$ integrin binding to SIV does not improve virologic control. <i>Science</i> , 2019, 365, 1033-1036.	6.0	31

#	ARTICLE	IF	CITATIONS
91	Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. <i>Lancet HIV</i> , 2019, 6, e667-e679.	2.1	67
92	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2019, 15, e1008026.	2.1	56
93	Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields. <i>Immunity</i> , 2019, 51, 724-734.e4.	6.6	13
94	Sera Antibody Repertoire Analyses Reveal Mechanisms of Broad and Pandemic Strain Neutralizing Responses after Human Norovirus Vaccination. <i>Immunity</i> , 2019, 50, 1530-1541.e8.	6.6	71
95	Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. <i>PLoS ONE</i> , 2019, 14, e0215163.	1.1	41
96	Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine. <i>Science Immunology</i> , 2019, 4, .	5.6	40
97	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. <i>Immunity</i> , 2019, 50, 677-691.e13.	6.6	77
98	Associating HIV-1 envelope glycoprotein structures with states on the Åvirus observed by smFRET. <i>Nature</i> , 2019, 568, 415-419.	13.7	156
99	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. <i>PLoS Pathogens</i> , 2019, 15, e1007632.	2.1	20
100	CD4 receptor diversity in chimpanzees protects against SIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3229-3238.	3.3	21
101	Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. <i>Nature Immunology</i> , 2019, 20, 362-372.	7.0	211
102	Improvement of antibody functionality by structure-guided paratope engraftment. <i>Nature Communications</i> , 2019, 10, 721.	5.8	27
103	Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry. <i>Nature Communications</i> , 2019, 10, 47.	5.8	50
104	Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. <i>Structure</i> , 2019, 27, 196-206.e6.	1.6	69
105	Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B. <i>Pathogens and Immunity</i> , 2019, 4, 294.	1.4	26
106	Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. <i>Journal of Virology</i> , 2018, 92, .	1.5	155
107	A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers. <i>Cell Reports</i> , 2018, 23, 584-595.	2.9	93
108	Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. <i>ACS Infectious Diseases</i> , 2018, 4, 788-796.	1.8	65

#	ARTICLE	IF	CITATIONS
109	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. <i>Cell Reports</i> , 2018, 22, 1798-1809.	2.9	52
110	A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope. <i>Immunity</i> , 2018, 48, 500-513.e6.	6.6	66
111	Unprecedented Role of Hybrid N-Glycans as Ligands for HIV-1 Broadly Neutralizing Antibodies. <i>Journal of the American Chemical Society</i> , 2018, 140, 5202-5210.	6.6	33
112	A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. <i>Nature Medicine</i> , 2018, 24, 408-416.	15.2	235
113	Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11369-E11378.	3.3	59
114	Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12265-12270.	3.3	70
115	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. <i>Immunity</i> , 2018, 49, 1162-1174.e8.	6.6	61
116	Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. <i>Nature Communications</i> , 2018, 9, 4136.	5.8	11
117	Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. <i>Cell Reports</i> , 2018, 25, 893-908.e7.	2.9	91
118	HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure. <i>Immunity</i> , 2018, 48, 855-871.	6.6	277
119	HIV-1 Env trimer opens through an asymmetric intermediate in which individual protomers adopt distinct conformations. <i>ELife</i> , 2018, 7, .	2.8	127
120	Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies. <i>Immunity</i> , 2018, 49, 301-311.e5.	6.6	110
121	Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV. <i>PLoS Pathogens</i> , 2018, 14, e1007159.	2.1	46
122	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. <i>Nature Medicine</i> , 2018, 24, 857-867.	15.2	256
123	Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer. <i>Cell Host and Microbe</i> , 2018, 23, 832-844.e6.	5.1	43
124	Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. <i>PLoS ONE</i> , 2018, 13, e0193773.	1.1	24
125	Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core. <i>ELife</i> , 2018, 7, .	2.8	32
126	Antibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1. <i>Immunological Reviews</i> , 2017, 275, 108-128.	2.8	32

#	ARTICLE	IF	CITATIONS
127	Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer. <i>Nature Structural and Molecular Biology</i> , 2017, 24, 370-378.	3.6	94
128	Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3124-3153.	2.9	58
129	Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. <i>Journal of Virology</i> , 2017, 91, .	1.5	81
130	What Are the Most Powerful Immunogen Design Vaccine Strategies?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a029470.	2.3	25
131	Insights from NMR Spectroscopy into the Conformational Properties of Manâ€9 and Its Recognition by Two HIV Binding Proteins. <i>ChemBioChem</i> , 2017, 18, 764-771.	1.3	18
132	Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop. <i>Immunity</i> , 2017, 46, 777-791.e10.	6.6	81
133	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. <i>Cell Reports</i> , 2017, 19, 719-732.	2.9	160
134	Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate. <i>Journal of Virology</i> , 2017, 91, .	1.5	30
135	How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 229-240.	1.5	66
136	Protection of calves by a prefusion-stabilized bovine RSV F vaccine. <i>Npj Vaccines</i> , 2017, 2, 7.	2.9	38
137	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	81
138	Free Energy Perturbation Calculation of Relative Binding Free Energy between Broadly Neutralizing Antibodies and the gp120 Glycoprotein of HIV-1. <i>Journal of Molecular Biology</i> , 2017, 429, 930-947.	2.0	82
139	Preferential induction of cross-group influenza A hemagglutinin stemâ€“specific memory B cells after H7N9 immunization in humans. <i>Science Immunology</i> , 2017, 2, .	5.6	84
140	The Î²20â€“Î²21 of gp120 is a regulatory switch for HIV-1 Env conformational transitions. <i>Nature Communications</i> , 2017, 8, 1049.	5.8	88
141	Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. <i>Nature Chemical Biology</i> , 2017, 13, 1115-1122.	3.9	110
142	Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F. <i>Journal of Virology</i> , 2017, 91, .	1.5	15
143	Microsecond Dynamics and Network Analysis of the HIV-1 SOSIP Env Trimer Reveal Collective Behavior and Conserved Microdomains of the Glycan Shield. <i>Structure</i> , 2017, 25, 1631-1639.e2.	1.6	42
144	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. <i>Science</i> , 2017, 358, 85-90.	6.0	225

#	ARTICLE	IF	CITATIONS
145	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	87
146	Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8614-8619.	3.3	42
147	Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains. <i>Cell Reports</i> , 2017, 21, 2992-3002.	2.9	69
148	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. <i>Cell Reports</i> , 2017, 21, 3681-3690.	2.9	97
149	Gene-Specific Substitution Profiles Describe the Types and Frequencies of Amino Acid Changes during Antibody Somatic Hypermutation. <i>Frontiers in Immunology</i> , 2017, 8, 537.	2.2	82
150	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. <i>PLoS Pathogens</i> , 2017, 13, e1006148.	2.1	51
151	Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus. <i>PLoS ONE</i> , 2017, 12, e0186854.	1.1	42
152	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. <i>PLoS Pathogens</i> , 2017, 13, e1006074.	2.1	33
153	SONAR: A High-Throughput Pipeline for Inferring Antibody Ontogenies from Longitudinal Sequencing of B Cell Transcripts. <i>Frontiers in Immunology</i> , 2016, 7, 372.	2.2	67
154	Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection. <i>PLoS Computational Biology</i> , 2016, 12, e1004940.	1.5	35
155	Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. <i>PLoS Pathogens</i> , 2016, 12, e1005537.	2.1	51
156	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. <i>Cell</i> , 2016, 165, 813-826.	13.5	379
157	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. <i>Journal of Virology</i> , 2016, 90, 5899-5914.	1.5	62
158	Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. <i>Science</i> , 2016, 352, 828-833.	6.0	310
159	Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. <i>Journal of Virology</i> , 2016, 90, 10220-10235.	1.5	32
160	Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. <i>Cell</i> , 2016, 166, 1471-1484.e18.	13.5	198
161	Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies. <i>Structure</i> , 2016, 24, 1346-1357.	1.6	35
162	Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 811-820.	3.6	110

#	ARTICLE	IF	CITATIONS
163	Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. <i>Cell</i> , 2016, 166, 609-623.	13.5	270
164	Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. <i>Immunity</i> , 2016, 45, 1108-1121.	6.6	304
165	Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. <i>Nature Medicine</i> , 2016, 22, 1456-1464.	15.2	271
166	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3413-22.	3.3	170
167	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. <i>Cell</i> , 2016, 165, 449-463.	13.5	305
168	Modular synthesis of N-glycans and arrays for the hetero-ligand binding analysis of HIV antibodies. <i>Nature Chemistry</i> , 2016, 8, 338-346.	6.6	97
169	Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody. <i>Journal of Virology</i> , 2016, 90, 2740-2755.	1.5	58
170	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 81-90.	3.6	162
171	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , 2016, 90, 76-91.	1.5	205
172	Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8. <i>PLoS ONE</i> , 2016, 11, e0157409.	1.1	44
173	Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus. <i>PLoS ONE</i> , 2016, 11, e0159709.	1.1	27
174	Effective Isotope Labeling of Proteins in a Mammalian Expression System. <i>Methods in Enzymology</i> , 2015, 565, 289-307.	0.4	9
175	Crystal structure of a fully glycosylated HIV-1 gp120 core reveals a stabilizing role for the glycan at Asn262. <i>Proteins: Structure, Function and Bioinformatics</i> , 2015, 83, 590-596.	1.5	42
176	A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus. <i>PLoS ONE</i> , 2015, 10, e0128779.	1.1	38
177	Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. <i>Journal of Virology</i> , 2015, 89, 5318-5329.	1.5	125
178	HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 765-783.	1.5	34
179	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. <i>Cell</i> , 2015, 161, 1280-1292.	13.5	305
180	AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. <i>Nature</i> , 2015, 519, 87-91.	13.7	265

#	ARTICLE	IF	CITATIONS
181	Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. <i>PLoS Pathogens</i> , 2015, 11, e1004932.	2.1	141
182	Evaluation of candidate vaccine approaches for MERS-CoV. <i>Nature Communications</i> , 2015, 6, 7712.	5.8	258
183	Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1. <i>Journal of Virology</i> , 2015, 89, 8840-8854.	1.5	51
184	Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. <i>Nature Structural and Molecular Biology</i> , 2015, 22, 522-531.	3.6	333
185	Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate. <i>Journal of Virology</i> , 2015, 89, 9499-9510.	1.5	58
186	Eliminating antibody polyreactivity through addition of N-linked glycosylation. <i>Protein Science</i> , 2015, 24, 1019-1030.	3.1	11
187	Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. <i>Cell</i> , 2015, 161, 470-485.	13.5	226
188	Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2015, 89, 5895-5903.	1.5	92
189	Activation and lysis of human CD4 cells latently infected with HIV-1. <i>Nature Communications</i> , 2015, 6, 8447.	5.8	88
190	Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2015, 89, 8334-8345.	1.5	100
191	Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. <i>Science Translational Medicine</i> , 2015, 7, 309ra162.	5.8	312
192	Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. <i>Nature Medicine</i> , 2015, 21, 1332-1336.	15.2	215
193	Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. <i>Nature Medicine</i> , 2015, 21, 1065-1070.	15.2	567
194	Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas. <i>MBio</i> , 2015, 6, .	1.8	25
195	Penetrating the Glycan Shield on HIV-1. <i>FASEB Journal</i> , 2015, 29, 106.3.	0.2	0
196	Crystal Structures of HIV-1 gp120 Envelope Glycoprotein in Complex with NBD Analogues That Target the CD4-Binding Site. <i>PLoS ONE</i> , 2014, 9, e85940.	1.1	49
197	Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. <i>Science Translational Medicine</i> , 2014, 6, 243ra88.	5.8	222
198	Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6. <i>Journal of Virology</i> , 2014, 88, 2426-2441.	1.5	41

#	ARTICLE	IF	CITATIONS
199	Stapled HIV-1 peptides recapitulate antigenic structures and engage broadly neutralizing antibodies. <i>Nature Structural and Molecular Biology</i> , 2014, 21, 1058-1067.	3.6	69
200	NEP: web server for epitope prediction based on antibody neutralization of viral strains with diverse sequences. <i>Nucleic Acids Research</i> , 2014, 42, W64-W71.	6.5	16
201	Antibodies VRC01 and 10E8 Neutralize HIV-1 with High Breadth and Potency Even with Ig-Framework Regions Substantially Reverted to Germline. <i>Journal of Immunology</i> , 2014, 192, 1100-1106.	0.4	86
202	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , 2014, 509, 55-62.	13.7	681
203	Structure-Based Design, Synthesis and Validation of CD4-Mimetic Small Molecule Inhibitors of HIV-1 Entry: Conversion of a Viral Entry Agonist to an Antagonist. <i>Accounts of Chemical Research</i> , 2014, 47, 1228-1237.	7.6	88
204	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i> . <i>Journal of Virology</i> , 2014, 88, 12669-12682.	1.5	248
205	Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies. <i>Cell Host and Microbe</i> , 2014, 16, 304-313.	5.1	137
206	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. <i>Cell</i> , 2014, 158, 481-491.	13.5	266
207	Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. <i>Science</i> , 2014, 346, 759-763.	6.0	439
208	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. <i>Nature</i> , 2014, 514, 455-461.	13.7	702
209	Hyperglycosylated Stable Core Immunogens Designed To Present the CD4 Binding Site Are Preferentially Recognized by Broadly Neutralizing Antibodies. <i>Journal of Virology</i> , 2014, 88, 14002-14016.	1.5	43
210	Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. <i>Nature</i> , 2014, 515, 138-142.	13.7	400
211	Transplanting Supersites of HIV-1 Vulnerability. <i>PLoS ONE</i> , 2014, 9, e99881.	1.1	51
212	Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies. <i>Immunity</i> , 2013, 39, 245-258.	6.6	332
213	Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies. <i>Nature Chemical Biology</i> , 2013, 9, 521-526.	3.9	106
214	Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. <i>Nature Reviews Immunology</i> , 2013, 13, 693-701.	10.6	302
215	Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody. <i>Science</i> , 2013, 340, 1113-1117.	6.0	656
216	Structural Basis for Highly Effective HIV-1 Neutralization by CD4-Mimetic Mini-proteins Revealed by 1.5-Å Cocrystal Structure of gp120 and M48U1. <i>Structure</i> , 2013, 21, 1018-1029.	1.6	29

#	ARTICLE	IF	CITATIONS
217	Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04. <i>Journal of Virology</i> , 2013, 87, 2294-2306.	1.5	34
218	Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus. <i>Science</i> , 2013, 342, 592-598.	6.0	797
219	Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization. <i>Cell</i> , 2013, 153, 126-138.	13.5	478
220	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. <i>Nature</i> , 2013, 496, 469-476.	13.7	961
221	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. <i>Immunity</i> , 2013, 38, 176-186.	6.6	374
222	Mining the antibodyome for HIV-1 neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6470-6475.	3.3	142
223	Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization. <i>Science</i> , 2013, 340, 751-756.	6.0	213
224	Structural basis for diverse N-glycan recognition by HIV-1 neutralizing V1/V2-directed antibody PG16. <i>Nature Structural and Molecular Biology</i> , 2013, 20, 804-813.	3.6	257
225	Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 382-392.	1.5	27
226	Heavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding Sites. <i>Journal of Virology</i> , 2013, 87, 10173-10181.	1.5	22
227	De novo identification of VRC01 class HIV-1 neutralizing antibodies by next-generation sequencing of B-cell transcripts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4088-97.	3.3	105
228	Residue-Level Prediction of HIV-1 Antibody Epitopes Based on Neutralization of Diverse Viral Strains. <i>Journal of Virology</i> , 2013, 87, 10047-10058.	1.5	64
229	N332-Directed Broadly Neutralizing Antibodies Use Diverse Modes of HIV-1 Recognition: Inferences from Heavy-Light Chain Complementations of Function. <i>PLoS ONE</i> , 2013, 8, e55701.	1.1	38
230	Early Low-Titer Neutralizing Antibodies Impede HIV-1 Replication and Select for Virus Escape. <i>PLoS Pathogens</i> , 2012, 8, e1002721.	2.1	159
231	PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4. <i>Journal of Virology</i> , 2012, 86, 4394-4403.	1.5	109
232	A Short Segment of the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Resistance to V1/V2 Neutralizing Antibodies. <i>Journal of Virology</i> , 2012, 86, 8319-8323.	1.5	76
233	Broad and Potent Neutralizing Antibody Responses Elicited in Natural HIV-2 Infection. <i>Journal of Virology</i> , 2012, 86, 947-960.	1.5	55
234	Computational prediction of N-linked glycosylation incorporating structural properties and patterns. <i>Bioinformatics</i> , 2012, 28, 2249-2255.	1.8	85

#	ARTICLE	IF	CITATIONS
235	Epitope Mapping of Broadly Neutralizing HIV-2 Human Monoclonal Antibodies. <i>Journal of Virology</i> , 2012, 86, 12115-12128.	1.5	27
236	Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies. <i>Immunity</i> , 2012, 37, 412-425.	6.6	417
237	Structural Basis for Broad Detection of Genogroup II Noroviruses by a Monoclonal Antibody That Binds to a Site Occluded in the Viral Particle. <i>Journal of Virology</i> , 2012, 86, 3635-3646.	1.5	75
238	Peptides from Second Extracellular Loop of C-C Chemokine Receptor Type 5 (CCR5) Inhibit Diverse Strains of HIV-1. <i>Journal of Biological Chemistry</i> , 2012, 287, 15076-15086.	1.6	24
239	Mammalian Expression of Isotopically Labeled Proteins for NMR Spectroscopy. <i>Advances in Experimental Medicine and Biology</i> , 2012, 992, 197-211.	0.8	10
240	Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. <i>Nature</i> , 2012, 491, 406-412.	13.7	753
241	Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design. <i>Journal of Virology</i> , 2012, 86, 4688-4692.	1.5	159
242	Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 5663-5668.	3.3	222
243	Somatic populations of PGT135-137 HIV-1-neutralizing antibodies identified by 454 pyrosequencing and bioinformatic. <i>Frontiers in Microbiology</i> , 2012, 3, 315.	1.5	70
244	The changing face of HIV vaccine research. <i>Journal of the International AIDS Society</i> , 2012, 15, 17407.	1.2	47
245	Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4382-4396.	2.9	90
246	Computation-Guided Backbone Grafting of a Discontinuous Motif onto a Protein Scaffold. <i>Science</i> , 2011, 334, 373-376.	6.0	212
247	Structure-Based Identification and Neutralization Mechanism of Tyrosine Sulfate Mimetics That Inhibit HIV-1 Entry. <i>ACS Chemical Biology</i> , 2011, 6, 1069-1077.	1.6	31
248	Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. <i>Nature Structural and Molecular Biology</i> , 2011, 18, 1235-1243.	3.6	86
249	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. <i>Journal of Virology</i> , 2011, 85, 9998-10009.	1.5	393
250	Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing. <i>Science</i> , 2011, 333, 1593-1602.	6.0	788
251	Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus. <i>Journal of Molecular Biology</i> , 2011, 409, 853-866.	2.0	100
252	Mammalian production of an isotopically enriched outer domain of the HIV-1 gp120 glycoprotein for NMR spectroscopy. <i>Journal of Biomolecular NMR</i> , 2011, 50, 197-207.	1.6	18

#	ARTICLE	IF	CITATIONS
253	Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1. <i>Journal of Virology</i> , 2011, 85, 2524-2535.	1.5	46
254	Progress in the rational design of an AIDS vaccine. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2011, 366, 2759-2765.	1.8	50
255	Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies. <i>Journal of Virology</i> , 2011, 85, 11401-11408.	1.5	80
256	Rational Design of Vaccines to Elicit Broadly Neutralizing Antibodies to HIV-1. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2011, 1, a007278-a007278.	2.9	135
257	Vaccine Design Reaches the Atomic Level. <i>Science Translational Medicine</i> , 2011, 3, 91ps29.	5.8	4
258	Crystal Structures of GII.10 and GII.12 Norovirus Protruding Domains in Complex with Histo-Blood Group Antigens Reveal Details for a Potential Site of Vulnerability. <i>Journal of Virology</i> , 2011, 85, 6687-6701.	1.5	113
259	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. <i>Nature</i> , 2011, 480, 336-343.	13.7	794
260	Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes. <i>Journal of Virology</i> , 2011, 85, 7788-7796.	1.5	327
261	Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their Recognition by Antibodies. <i>Journal of Virology</i> , 2011, 85, 4578-4585.	1.5	43
262	Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp41. <i>PLoS ONE</i> , 2011, 6, e27824.	1.1	75
263	Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. <i>Journal of Virological Methods</i> , 2010, 168, 155-161.	1.0	35
264	Structural basis of respiratory syncytial virus neutralization by motavizumab. <i>Nature Structural and Molecular Biology</i> , 2010, 17, 248-250.	3.6	156
265	Elicitation of structure-specific antibodies by epitope scaffolds. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 17880-17887.	3.3	261
266	Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 1166-1171.	3.3	304
267	A V3 Loop-Dependent gp120 Element Disrupted by CD4 Binding Stabilizes the Human Immunodeficiency Virus Envelope Glycoprotein Trimer. <i>Journal of Virology</i> , 2010, 84, 3147-3161.	1.5	64
268	Local Conformational Stability of HIV-1 gp120 in Unliganded and CD4-Bound States as Defined by Amide Hydrogen/Deuterium Exchange. <i>Journal of Virology</i> , 2010, 84, 10311-10321.	1.5	32
269	Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F. <i>Journal of Virology</i> , 2010, 84, 12236-12244.	1.5	105
270	Relationship between Antibody 2F5 Neutralization of HIV-1 and Hydrophobicity of Its Heavy Chain Third Complementarity-Determining Region. <i>Journal of Virology</i> , 2010, 84, 2955-2962.	1.5	106

#	ARTICLE	IF	CITATIONS
271	Topological Layers in the HIV-1 gp120 Inner Domain Regulate gp41 Interaction and CD4-Triggered Conformational Transitions. <i>Molecular Cell</i> , 2010, 37, 656-667.	4.5	194
272	Expression-System-Dependent Modulation of HIV-1 Envelope Glycoprotein Antigenicity and Immunogenicity. <i>Journal of Molecular Biology</i> , 2010, 403, 131-147.	2.0	67
273	Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01. <i>Science</i> , 2010, 329, 811-817.	6.0	1,050
274	Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. <i>Science</i> , 2010, 329, 856-861.	6.0	1,600
275	Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1. <i>Journal of Virology</i> , 2010, 84, 8098-8110.	1.5	209
276	Structural Biology and the Design of Effective Vaccines for HIV-1 and Other Viruses. , 2010, , 387-402.		4
277	HIV-1 Receptor Interactions. , 2010, , 97-101.		0
278	Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment. <i>Journal of Virology</i> , 2009, 83, 10892-10907.	1.5	86
279	Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma. <i>Journal of Virology</i> , 2009, 83, 1240-1259.	1.5	67
280	Structure-Based Stabilization of HIV-1 gp120 Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site. <i>PLoS Pathogens</i> , 2009, 5, e1000445.	2.1	113
281	Enhanced Exposure of the CD4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp120 Domain. <i>Journal of Virology</i> , 2009, 83, 5077-5086.	1.5	43
282	HIV-1 and influenza antibodies: seeing antigens in new ways. <i>Nature Immunology</i> , 2009, 10, 573-578.	7.0	128
283	Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120. <i>Science</i> , 2009, 326, 1123-1127.	6.0	271
284	Small-Molecule CD4 Mimics Interact with a Highly Conserved Pocket on HIV-1 gp120. <i>Structure</i> , 2008, 16, 1689-1701.	1.6	160
285	Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4. <i>Science</i> , 2007, 317, 1930-1934.	6.0	379
286	Characterization of Human Immunodeficiency Virus Type 1 Monomeric and Trimeric gp120 Glycoproteins Stabilized in the CD4-Bound State: Antigenicity, Biophysics, and Immunogenicity. <i>Journal of Virology</i> , 2007, 81, 5579-5593.	1.5	101
287	Structural definition of a conserved neutralization epitope on HIV-1 gp120. <i>Nature</i> , 2007, 445, 732-737.	13.7	715
288	Refolding the envelope. <i>Nature</i> , 2005, 433, 815-816.	13.7	34

#	ARTICLE	IF	CITATIONS
289	Scorpion-Toxin Mimics of CD4 in Complex with Human Immunodeficiency Virus gp120. <i>Structure</i> , 2005, 13, 755-768.	1.6	107
290	Structure of a V3-Containing HIV-1 gp120 Core. <i>Science</i> , 2005, 310, 1025-1028.	6.0	696
291	Antigenic conservation and immunogenicity of the HIV coreceptor binding site. <i>Journal of Experimental Medicine</i> , 2005, 201, 1407-1419.	4.2	296
292	Soluble Mimetics of Human Immunodeficiency Virus Type 1 Viral Spikes Produced by Replacement of the Native Trimerization Domain with a Heterologous Trimerization Motif: Characterization and Ligand Binding Analysis. <i>Journal of Virology</i> , 2005, 79, 9954-9969.	1.5	67
293	Interfacial metal and antibody recognition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 14575-14580.	3.3	29
294	Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope. <i>Journal of Virology</i> , 2004, 78, 10724-10737.	1.5	452
295	Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 2706-2711.	3.3	278
296	HIV vaccine design and the neutralizing antibody problem. <i>Nature Immunology</i> , 2004, 5, 233-236.	7.0	721
297	The 447-52D Antibody: Hitting HIV-1 Where Its Armor Is Thickest. <i>Structure</i> , 2004, 12, 173-174.	1.6	3
298	Enhancing Protein Crystallization through Precipitant Synergy. <i>Structure</i> , 2003, 11, 1061-1070.	1.6	75
299	Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. <i>Virology</i> , 2003, 313, 387-400.	1.1	158
300	Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. <i>Virology</i> , 2003, 315, 124-134.	1.1	76
301	Antibody neutralization and escape by HIV-1. <i>Nature</i> , 2003, 422, 307-312.	13.7	2,233
302	Tyrosine Sulfation of Human Antibodies Contributes to Recognition of the CCR5 Binding Region of HIV-1 gp120. <i>Cell</i> , 2003, 114, 161-170.	13.5	186
303	Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2003, 77, 10557-10565.	1.5	343
304	CD4 Binding Site Antibodies Inhibit Human Immunodeficiency Virus gp120 Envelope Glycoprotein Interaction with CCR5. <i>Journal of Virology</i> , 2003, 77, 713-718.	1.5	26
305	HIV-1 Receptor Interactions. , 2003, , 99-104.		0
306	The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120. <i>Journal of Virology</i> , 2002, 76, 7293-7305.	1.5	528

#	ARTICLE	IF	CITATIONS
307	Highly Stable Trimers Formed by Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Fused with the Trimeric Motif of T4 Bacteriophage Fibrin. <i>Journal of Virology</i> , 2002, 76, 4634-4642.	1.5	261
308	Mutagenic Stabilization and/or Disruption of a CD4-Bound State Reveals Distinct Conformations of the Human Immunodeficiency Virus Type 1 gp120 Envelope Glycoprotein. <i>Journal of Virology</i> , 2002, 76, 9888-9899.	1.5	177
309	HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. <i>Nature</i> , 2002, 420, 678-682.	13.7	832
310	Structures of HIV-1 gp120 Envelope Glycoproteins from Laboratory-Adapted and Primary Isolates. <i>Structure</i> , 2000, 8, 1329-1339.	1.6	358
311	Oligomeric Modeling and Electrostatic Analysis of the gp120 Envelope Glycoprotein of Human Immunodeficiency Virus. <i>Journal of Virology</i> , 2000, 74, 1961-1972.	1.5	248
312	Probability Analysis of Variational Crystallization and Its Application to gp120, The Exterior Envelope Glycoprotein of Type 1 Human Immunodeficiency Virus (HIV-1). <i>Journal of Biological Chemistry</i> , 1999, 274, 4115-4123.	1.6	106
313	Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. <i>Nature</i> , 1998, 393, 648-659.	13.7	2,788
314	The antigenic structure of the HIV gp120 envelope glycoprotein. <i>Nature</i> , 1998, 393, 705-711.	13.7	1,152
315	A Conserved HIV gp120 Glycoprotein Structure Involved in Chemokine Receptor Binding. <i>Science</i> , 1998, 280, 1949-1953.	6.0	819
316	Analysis of the Interaction of Antibodies with a Conserved, Enzymatically Deglycosylated Core of the HIV Type 1 Envelope Glycoprotein 120. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 191-198.	0.5	56
317	Dimeric association and segmental variability in the structure of human CD4. <i>Nature</i> , 1997, 387, 527-530.	13.7	259
318	Crystal structure of an HIV-binding recombinant fragment of human CD4. <i>Nature</i> , 1990, 348, 419-426.	13.7	599